Inventor · disambiguated record
Brian W. Budzik
Also filed as: BUDZIK BRIAN · BUDZIK BRIAN W
21 granted patents·5 pending applications·191 citations·filing 2005–2022
94Inventor score
Files withSIRNA THERAPEUTICS INC9BUDZIK BRIAN W5BUDZIK BRIAN4GLAXOSMITHKLINE IP NO 2 LTD3GLAXO GROUP LTD2
Top patents by PatentIndex Score
26 records- 0198US9604908B2Diether based biodegradable cationic lipids for siRNA deliverySIRNA THERAPEUTICS INC·Filed 2016·Granted Mar 28, 2017·39 cites·6 claims
- 0296US8748667B2Low molecular weight cationic lipids for oligonucleotide deliveryBUDZIK BRIAN W·Filed 2011·Granted Jun 10, 2014·96 cites·3 claims
- 0393US9643916B2Low molecular weight cationic lipids for oligonucleotide deliverySIRNA THERAPEUTICS INC·Filed 2016·Granted May 9, 2017·5 cites·6 claims
- 0493US8802863B2Amino alcohol cationic lipids for oligonucleotide deliveryBUDZIK BRIAN W·Filed 2011·Granted Aug 12, 2014·10 cites·4 claims
- 0590US9669097B2Low molecular weight cationic lipids for oligonucleotide deliverySTANTON MATTHEW G·Filed 2011·Granted Jun 6, 2017·15 cites·7 claims
- 0690US9062021B2Low molecular weight cationic lipids for oligonucleotide deliverySIRNA THERAPEUTICS INC·Filed 2014·Granted Jun 23, 2015·6 cites·6 claims
- 0788US9315437B2Low molecular weight cationic lipids for oligonucleotide deliverySIRNA THERAPEUTICS INC·Filed 2015·Granted Apr 19, 2016·3 cites·6 claims
- 0887US9446132B2Diether based biodegradable cationic lipids for siRNA deliverySIRNA THERAPEUTICS INC·Filed 2013·Granted Sep 20, 2016·4 cites·7 claims
- 0984US10576155B2Low molecular weight cationic lipids for oligonucleotide deliverySIRNA THERAPEUTICS INC·Filed 2017·Granted Mar 3, 2020·3 cites·8 claims
- 1080US11911475B2Low molecular weight cationic lipids for oligonucleotide deliverySIRNA THERAPEUTICS INC·Filed 2022·Granted Feb 27, 2024·0 cites·8 claims
- 1180US8283364B2Compounds which have activity at M1 receptor and their uses in medicineBUDZIK BRIAN·Filed 2006·Granted Oct 9, 2012·5 cites·8 claims
- 1278US9044512B2Amino alcohol cationic lipids for oligonucleotide deliverySIRNA THERAPEUTICS INC·Filed 2014·Granted Jun 2, 2015·1 cites·8 claims
- 1373US11413348B2Low molecular weight cationic lipids for oligonucleotide deliverySIRNA THERAPEUTICS INC·Filed 2020·Granted Aug 16, 2022·0 cites·25 claims
- 1471US8481566B2Compounds which have activity at M1 receptor and their uses in medicineBUDZIK BRIAN·Filed 2007·Granted Jul 9, 2013·1 cites·7 claims
- 1570US8288413B2Benzimidazolones which have activity at M1 receptorBUDZIK BRIAN·Filed 2006·Granted Oct 16, 2012·1 cites·7 claims
- 1669US10588891B2TRPV4 antagonistsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2017·Granted Mar 17, 2020·1 cites·21 claims
- 1769US8288412B2Compounds which have activity at M1 receptor and their uses in medicineBUDZIK BRIAN·Filed 2006·Granted Oct 16, 2012·1 cites·10 claims
- 1855US8431590B2Spiroindolines as modulators of chemokine receptorsBUDZIK BRIAN W·Filed 2008·Granted Apr 30, 2013·0 cites·10 claims
- 1953US11229623B2TRPV4 antagonistsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2020·Granted Jan 25, 2022·0 cites·21 claims
- 2047US2011124671A1Spiroindenes and spiroindanes as modulators of chemokine receptorsBUDZIK BRIAN W·Filed 2008·Application pending·0 cites
- 2142US7932247B2M3 muscarinic acetylcholine receptor antagonistsGLAXO GROUP LTD·Filed 2005·Granted Apr 26, 2011·0 cites·4 claims
- 2242US2009142279A1Novel m3 muscarinic acetylcholine receptor antagonistsBUDZIK BRIAN W·Filed 2005·Application pending·0 cites
- 2341US2020071310A1N-aryl pyrazoles as nrf2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Application pending·0 cites
- 2439US10590077B2TRPV4 antagonistsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2017·Granted Mar 17, 2020·0 cites·20 claims
- 2539US2020031820A13-carboxylic acid pyrroles as nrf2 regulatorsGLSXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD·Filed 2017·Application pending·0 cites
- 2639US2009253908A1Novel m3 muscarinic acetylchoine receptor antagonistsGLAXO GROUP LTD·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Brian W. Budzik files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →